刘后春 秦勇 杨海东

[摘要]目的分析首發精神分裂症患者采用齐拉西酮治疗的临床疗效及所致不良反应。方法选择2020年1月至2021年4月连云港市第四人民医院收诊治疗首发精神分裂症患者120例进行回顾性研究，根据治疗方法差异将患者分为对照组（ n=60）和观察组（ n=60），对照组患者采用药物利培酮治疗，观察组患者采用药物齐拉西酮治疗，对比两组临床治疗效果，评估两组患者治疗前后症状改善情况。观察并统计各组患者用药后出现不良反应的症状与总发生率。结果两组患者临床治疗总有效率比较，差异无统计学意义（P >0.05）。两组患者治疗前症状评分结果比较，差异无统计学意义（ P >0.05），治疗后，观察组患者 PANSS 阳性量表评分（14.26±3.02）分、阴性量表评分（13.09±2.11）分、一般精神病理量表评分（23.39±2.14）分及补充项目评分（5.22±1.01）分均低于对照组，差异有统计学意义（ P <0.05）。同时，观察组患者治疗后不良反应总发生率为3.33%，低于对照组的18.33%，差异有统计学意义（ P <0.05）。结论首发精神分裂症患者采用齐拉西酮治疗优势在于效果明显、所引起的不良反应少，安全性高，值得临床运用且推广。

[关键词]齐拉西酮;首发精神分裂症;症状评估;不良反应

[中图分类号] R749.3 [文献标识码] A  [文章编号]2095-0616（2021）22-0076-04

A study of the curative effect of ziprasidone on first-episode schizophrenia and the adverse reactions of the patients

LIUHouchun1 QINYong2 YANGHaidong

1. Department of Pharmacy， the Fourth People's Hospital of Lianyungang， Jiangsu， Lianyungang 222001， China;2. Department of Psychiatry I， the Fourth People's Hospital of Lianyungang， Jiangsu， Lianyungang 222001， China;3. Department of Psychiatry II， the Fourth People's Hospital of Lianyungang， Jiangsu， Lianyungang 222001， China

[Abstract] Objective To analyze the clinical effect of ziprasidone on first-episode schizophrenic patients and the incurred adverse reactions （ARs）. Methods A total of 120 first-episode schizophrenic patients admitted to and treated in the Fourth People's Hospital of Lianyungang from January 2020 to April 2021 were selected for retrospective study. According to the difference of treatment methods， the patients were divided into the control group （n=60） and observation group （n=60）. The patients in the control group were treated with the medicine risperidone and the patients in the observation group were treated with the medicine ziprasidone. Clinical curative effect was compared， symptom amelioration of the two groups of patients before and after treatment was assessed. The symptoms and total incidence of ARs in each group after medication were observed and counted. Results The difference in total effective rate of clinical treatment between the two groups of patients was statistically insignificant （P >0.05）. The difference in the result of symptom score between the two groups of patients before treatment was statistically insignificant （P >0.05）. After treatment， the score of PANSS positive scale （14.26±3.02） of the patients in the observation group， the score of PANSS negative scale （13.09±2.11）， the score of general psychopathology scale （23.39±2.14） and the score of supplementary items （5.22±1.01） were all significantly lower than those in the control group， and the differences were statistically significant （P <0.05）. Meanwhile， the total incidence of ARs in the patients of the observation group after treatment was 3.33%， lower than that of the control group （P <0.05）. Conclusion The advantages of ziprasidone in treating first-episode schizophrenic patients include obvious effect， fewer ARs and high safety. It is worthy of clinical application and promotion.

[Key words] Ziprasidone; First-episode schizophrenia; Symptom assessment; Adverse reaction

精神分裂症是临床十分常见的疾病之一，目前病因尚未明晰，对患者的日常生活、健康等均造成损害。患者发病后，可能存在情感、认知、思维、感觉等功能障碍[1]。首发精神分裂症是指第一次出现精神分裂的症状表现，如果可以得到有效治疗，则能够促进患者精神功能恢复，一旦未得到良好治疗，则可能演变为慢性精神分裂症，迁延性精神分裂症等，增加治疗难度，加重对患者的伤害[2]。目前临床治疗首发精神分裂症多采取药物治疗方式，其中常用药物包括利培酮、齐拉西酮等，具有良好效果，但二者如何选择值得临床进一步研究[3]。本文回顾……